KPV: doses reported in published research

Sources checked 2026-10-07 · 1 cited study (0 human, 1 animal, 0 cell culture)

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13). Published dose data are from mouse colitis models; several papers describe KPV only in nanoparticle or hydrogel formulations.

No human data. no human studies or registered human trials of KPV were found.

Animal studies (1)

Animal doses are listed exactly as the studies report them. They are not converted to human amounts here; doses do not translate between species by body weight.

Animal Wild-type and PepT1-knockout mice (AOM/DSS colitis-associated tumour model)

Dose as reported: 100 µmol/L in drinking water
Route: Oral (drinking water)
Frequency / duration: During both DSS periods (7 days each)

Source wording: The KPV-treated group received 100 μmol/L KPV in their drinking water along with the DSS during both DSS cycles. with or without KPV for 7 days

Viennois E, Ingersoll SA, Ayyadurai S et al.. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016. PubMed PMID 27458604 ↗ · full text PMC4957955 ↗

Half-life

No half-life value was found in the sources reviewed for this page.

Two 2008 mouse colitis papers (PMID 18061177, 18092346) give KPV orally or by other routes but do not state the amount in their abstracts, and their full text is not open access.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.